TL;DR
- What it is: SLU-PP-332 is a synthetic small-molecule pan-agonist of estrogen-related receptors (ERR-alpha, beta, gamma), a class of orphan nuclear receptors central to mitochondrial biogenesis.
- Mechanism: Activates ERR transcriptional programs that drive mitochondrial biogenesis, fatty acid oxidation, type I muscle fiber gene expression, and endurance-like adaptations without exercise.
- Who it’s for: Endurance-focused athletes (research-only; banned in tested sport), obesity-related metabolic dysfunction, longevity stack experimenters.
- Differentiator: First-in-class ERR-alpha agonist. Distinct from PPAR-delta agonists (Cardarine) — different transcription factor, different gene set.
- Natural Plus angle: Research-only compound. Treat as a short, deliberate experiment, not a chronic substitute for actual training.
The exercise mimetic field has been searching for a clean ERR agonist for two decades. PPAR-delta agonists like Cardarine (GW-501516) deliver some of the same downstream effects, but they hit a different transcription factor and carry their own controversies. SLU-PP-332, developed at Saint Louis University and published in 2023, is the first reasonably selective small-molecule pan-ERR agonist to enter the research literature with strong rodent data on endurance, fat oxidation, and metabolic improvement. the enhanced man should know what this molecule does — even if commercial availability remains limited and human dosing is undefined.
Deep Biochemistry: Why ERR Activation Is Different From PPAR Activation
The estrogen-related receptors (ERR-alpha, ERR-beta, ERR-gamma; gene symbols ESRRA, ESRRB, ESRRG) are orphan nuclear receptors — they share structural homology with classic estrogen receptors but do not bind estrogen. They were “orphan” because no endogenous ligand was identified for years. They are now understood to be activated primarily by interaction with the coactivator PGC-1-alpha, the master regulator of mitochondrial biogenesis.
SLU-PP-332 is a synthetic small molecule that binds the err-alpha ligand binding domain with reasonable affinity (sub-micromolar EC50 in transactivation assays) and shows pan-agonist activity across the three ERR isoforms. The discovery work by Burris and colleagues at SLU showed that oral SLU-PP-332 administration in mice increased running endurance, drove mitochondrial biogenesis in skeletal muscle, increased fatty acid oxidation, and shifted muscle fiber composition toward more oxidative type I fibers — all without any exercise stimulus.
The downstream gene set activated by SLU-PP-332 overlaps significantly with what endurance training produces. Genes involved in oxidative phosphorylation, the TCA cycle, beta-oxidation, and muscle vasculature are all upregulated. PGC-1-alpha itself is a target gene of ERR-alpha (positive feedback loop), so a single dose triggers a self-amplifying transcriptional program. The pharmacology is genuinely novel.
Plasma half-life of SLU-PP-332 in rodents is several hours, and biological effects accumulate over days to weeks because mitochondrial biogenesis is a slow process — new mitochondria take time to be transcribed, translated, and assembled.
Tony huge laws of Biochemistry Physics: Law 5 — Independent Receptor Stacking
This compound is a textbook illustration of the tony huge Laws of Biochemistry Physics — specifically Law 5, Independent Receptor Stacking. ERR-alpha sits on a different signaling axis than PPAR-delta (Cardarine), AMPK (metformin, AICAR), or SIRT1 (resveratrol). All four pathways converge on mitochondrial biogenesis and fatty acid oxidation, but each approaches from a different angle.
Stacking compounds that hit independent receptors converging on the same metabolic outcome is where compounded effects come from. Stacking two PPAR-delta agonists is wasteful; stacking PPAR-delta with ERR-alpha may be additive because the receptor systems are independent. The principle is parallel-circuit thinking — different receptor inputs, same downstream wattage.
Natural Plus Protocol
Important caveat: SLU-PP-332 is research-only. It has not been administered to humans in any published trial. Self-experimentation carries unknown risks. The discussion here is mechanistic and based on rodent data. the enhanced man treats novel research compounds with appropriate caution.
Dosing (research literature): Mouse studies used 25–50 mg/kg via intraperitoneal or oral administration. Human-equivalent dose extrapolation suggests low single-digit milligrams per kilogram, but no validated human protocol exists. Underground reports vary widely.
Cycling: 4–8 weeks maximum, then off. the mitochondrial biogenesis program reaches a new equilibrium within 4–6 weeks, after which marginal benefit decreases.
Timing: Pre-training, if tolerated. Acute effects on fatty acid oxidation may amplify training-induced adaptations.
What to monitor: Resting heart rate (mitochondrial fitness improves it), vo2 max if you can test, fasting glucose and insulin, lipid panel. Watch for any signs of cardiac stress in the early weeks.
Stacking Recommendations
Per Law 5, SLU-PP-332 stacks with compounds hitting independent metabolic pathways converging on mitochondrial fitness.
| Stack Compound | Pathway | Why It Synergizes |
|---|---|---|
| PQQ | Mitochondrial biogenesis cofactor | SLU-PP-332 transcribes new mitochondrial genes; PQQ supports the assembly process. |
| CoQ10 (Ubiquinol) | Electron transport chain | More mitochondria need more CoQ10 to function — substrate to match capacity. |
| Berberine | AMPK | AMPK independently drives mitochondrial fitness — different transcription factor, parallel effect. |
| L-Carnitine | Fatty acid mitochondrial entry | SLU-PP-332 upregulates fatty acid oxidation genes; carnitine ensures substrate gets into the mitochondria. |
Target Audience
Endurance athletes outside tested sport, men with metabolic syndrome who cannot tolerate sufficient exercise volume, longevity-focused biohackers experimenting with novel transcription-factor agonists, obese patients in research settings, and recovery from prolonged immobilization or illness. Not for: anyone in WADA-tested sport, men with active cardiovascular disease, or those who can simply train more.
Timeline / Results Table
| Timeframe | What to Expect |
|---|---|
| Week 1–2 | Subtle improvement in steady-state cardio. Slight reduction in perceived exertion at submax efforts. |
| Week 4 | Measurable improvements in endurance metrics. Resting heart rate trends down. fasting fatty acid oxidation rises. |
| Week 6–8 | Mitochondrial biogenesis reaches new plateau. Cycle off and assess sustained adaptations. |
| Post-cycle | Some adaptations persist; others regress. Re-cycle after a 6-month break if benefit was meaningful. |
Interesting Perspectives
The most fascinating aspect of SLU-PP-332 is what it implies about the future of metabolic medicine. Exercise is the single most powerful intervention humans have for preventing chronic disease — and the molecular signature of regular endurance exercise is well-mapped at the gene-expression level. ERR-alpha activation reproduces a substantial fraction of that signature pharmacologically. If the molecule is safe long-term in humans (a big if, given how new it is), it’s a candidate for treating populations that cannot exercise: severe COPD, end-stage CKD, paraplegia, and so on.
The contrarian tony huge take: the “exercise is the best medicine” argument has been used to dismiss every metabolic drug. But for a 65-year-old man with osteoarthritis who cannot generate the training volume needed for cardiovascular adaptation, an exercise mimetic isn’t a substitute for laziness — it’s a workaround for a physical limitation. The Enhanced Man uses pharmacology where it bridges what the body cannot do mechanically.
An emerging research angle: ERR-alpha is also expressed in cardiac tissue and is implicated in cardiac mitochondrial fitness. SLU-PP-332 in animal models showed cardiac biogenesis effects similar to those seen in skeletal muscle. The cardiovascular longevity implications are notable — but so is the risk of cardiac hypertrophy if the program is run too long.
Real-world pattern from the underground: very few users have experimented with SLU-PP-332 because supply has been extremely limited. Reports from those who have suggest a Cardarine-like endurance benefit with a slower onset, fewer subjective stimulation effects, and possibly a cleaner cardiovascular profile — but the sample size is tiny, and these reports cannot be considered reliable evidence.
References
References
- Billon C et al. “Synthetic ERRalpha/beta/gamma agonist induces an ERR-driven metabolic gene signature in skeletal muscle and improves endurance performance.” Journal of Pharmacology and Experimental Therapeutics, 2023.
- Audet-Walsh E, Giguère V. “The multiple universes of estrogen-related receptor alpha and gamma in metabolic control and related diseases.” Acta Pharmacologica Sinica, 2015.
- Mootha VK et al. “Errα and Gabpa/b specify PGC-1α-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle.” PNAS, 2004.
- Cunningham KF et al. “Estrogen-related receptors in skeletal muscle mitochondrial biogenesis and oxidative function.” Frontiers in Physiology, 2021.
- Wei W et al. “Ligands for orphan nuclear receptor ERRα reveal cellular mechanisms of mitochondrial regulation.” Nature Chemical Biology, 2016.
- Burris TP et al. “Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity.” Chemistry and Biology, 2012.
Frequently Asked Questions
SLU-PP-332 sits at the cutting edge of the exercise mimetic field. Compare with the Cardarine (GW-501516) deep dive for the PPAR-delta angle, and the mitochondrial optimization protocol for the broader cellular fitness framework. For training-side adaptations that compound any pharmacological intervention, see the Enhanced Athlete training protocol.
Bottom line: SLU-PP-332 is a first-in-class molecule with promising rodent data and unknown human safety. The mechanism is genuinely novel — it’s not a Cardarine knockoff. Treat it as a research-only experiment, watch the literature for human trials, and do not substitute it for training. The Enhanced Man uses pharmacology to amplify physical work, not to replace it.